Skip to main content

Advertisement

SpringerLink
Log in

Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

A second transurethral resection (TUR) has been recommended by guidelines for high-grade non-muscle-invasive bladder cancer (NMIBC). However, the impact of surgical quality and post-TUR intra-vesical instillation therapy on oncologic outcome still remains unclear for newly diagnosed NMIBC. We conducted a retrospective cohort study for the patients who underwent extensive TUR followed by appropriate intra-vesical therapy for newly diagnosed NMIBC to assess their oncological outcomes.

Methods

We treated a cohort of 150 patients with NMIBC by our single but extensive TUR protocol at Hirosaki University Hospital between January 2005 and May 2012. The extensive TUR procedure comprised complete resection of all visible tumors including the muscle layer with a separate cold cup-biopsy of the marginal bottom. After visible tumors resection, additional resection for 5 mm wider area around the first surgical margin was performed. TUR was conducted by three expert urologists who had common agreement with the extensive TUR. All patients received 50 mg of epirubicin instillation immediately after TUR. Out of 150 patients, 74 patients who had multiple tumors or high-grade T1 disease received 40 mg of bacillus Calmette–Guérin Tokyo 172 strain once a week for six consecutive weeks. Patients who received second TUR were not included. The endpoints in this study were the recurrence-, progression-free, cancer-specific, and overall survivals.

Results

The 5-year recurrence- and progression-free survival rates were 77.2 and 98.0 %, respectively. The 5-year cancer-specific and overall survival rates were 98.0 and 92.6 %, respectively. The 5-year recurrence- and progression-free survival rates in high-grade T1 disease were 77.1 and 97.6 %, respectively, which were not significantly different from those in the cohort with Ta or low-grade BC. Cystoscopy revealed that 93 % of the patients were tumor-free, at the first cystoscopy, and four patients (3 %) showed progression to stage T2 or higher disease during the first year.

Conclusion

While the present study has several limitations, including single-arm and retrospective nature, a single but extensive TUR combined with adjuvant intravesical treatment may have acceptable oncological outcomes in NMIBC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Holmämg S (2013) High-grade non-muscle-invasive bladder cancer: is re-resection necessary in all patients before intravesical bacillus Calmette–Guérin treatment? Scand J Urol 47:363–369

    Article  Google Scholar 

  2. Grimm M, Steinhoff C, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437

    Article  PubMed  Google Scholar 

  3. Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62–67

    Article  CAS  PubMed  Google Scholar 

  4. Babjuk M, Oosterlinck W, Sylvester R et al (2011) European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  5. Herr HW, Donat SM, Dalbagni G et al (2007) Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177:75–79

    Article  PubMed  Google Scholar 

  6. Babjuk M (2010) Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 58:191–192

    Article  PubMed  Google Scholar 

  7. Witjes JA, Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53:45–52

    Article  PubMed  Google Scholar 

  8. Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette–Guérin therapy. J Urol 148:797–801

    CAS  PubMed  Google Scholar 

  9. Bladder Urinary (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 497–505

    Google Scholar 

  10. Sylvester RJ, van der Meijden APM, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477

    Article  PubMed  Google Scholar 

  11. Yoneyama T, Ohyama C, Imai A et al (2008) Low-dose instillation therapy with bacillice Calmette–Guérin Tokyo 172 strain after transurethral resection: his torical cohort study. Urology 71:1161–1165

    Article  PubMed  Google Scholar 

  12. Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70

    Article  PubMed  Google Scholar 

  13. Herr HW (2011) Role of re-resection in non-muscle-invasive bladder cancer. Sci World J 11:283–288

    Article  Google Scholar 

  14. Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 58:185–190

    Article  PubMed  Google Scholar 

  15. Brausi M, Collette L, Kurth K et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41:523–531

    Article  PubMed  Google Scholar 

  16. Zurkirchen MA, Sulser T, Gaspert A et al (2004) Second TUR of superficialtransitional cell carcinoma of the bladder: a must even for experienced urologist. Urol Int 72:99–102

    Article  CAS  PubMed  Google Scholar 

  17. Mostafid H, Brausi M (2012) Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int 109:1579–1582

    Article  PubMed  Google Scholar 

  18. Akaza H, Hinotsu S, Aso Y et al (1995) Bacillus Calmette–Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 75:552–559

    Article  CAS  PubMed  Google Scholar 

  19. Oosterlinck W, Bono AV, Mack D et al (2001) Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol 40:515–517

    Article  CAS  PubMed  Google Scholar 

  20. Shelley MD, Court JB, Kynaston H et al. (2000) Intravesical bacillus Calmette–Guérin in Ta and T1 bladder cancer. Cochrane Database Syst Rev CD001986

  21. Sylvester RJ, van der MEIJDEN AP, Lamm DL (2002) Intravesical bacillus Calmette–Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan

    Takuya Koie, Chikara Ohyama, Shogo Hosogoe, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa & Kazuyuki Mori

Authors
  1. Takuya Koie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shogo Hosogoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hayato Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shingo Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takahiro Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasuhiro Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tohru Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuki Tobisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazuyuki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuya Koie.

Ethics declarations

Conflict of interest

All authors declare that there are no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koie, T., Ohyama, C., Hosogoe, S. et al. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol 47, 1509–1514 (2015). https://doi.org/10.1007/s11255-015-1048-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1048-3

Keywords

Search

Navigation